<DOC>
	<DOCNO>NCT02021110</DOCNO>
	<brief_summary>Rationale : Polycystic liver disease ( PLD ) rare disorder characterize &gt; 20 fluid-filled hepatic cyst . Polycystic liver present combination renal cyst manifestation autosomal dominant polycystic kidney disease ( ADPKD ) , isolated absence renal cyst autosomal dominant polycystic liver disease ( ADPLD PCLD ) . PLD patient confront symptom cause mass effect polycystic liver every day rest life . There standard therapeutic option symptomatic PLD patient . Current option fairly invasive efficacy moderate . Preliminary data research lab show ursodeoxycholic acid ( UDCA ) inhibit proliferation polycystic human cholangiocytes vitro normalization intracellular calcium level cystic cholangiocytes . The investigator also find daily oral administration UDCA 5 month PCK rat , animal model ARPKD spontaneously develop hepato-renal cystogenesis , result inhibition hepatic cystogenesis . The investigator hypothesize UDCA effective therapeutic tool reduce liver volume PLD . Objective : First , demonstrate whether UDCA-therapy effective reduce total liver volume PLD patient . Second , investigator want assess UDCA modifies quality life . Finally , investigator want assess safety tolerability . Study design : International , multicenter , randomize , control trial Study population : 34 subject ( 18 ≤age ≤ 80 year ) suffer symptomatic polycystic liver disease underlie diagnosis ( PCLD ADPKD ) , define ≥ 20 liver cyst CT-scan liver volume ≥ 2500 . Symptomatic define ECOG-PS ≥ 1 least three ten PLD symptom . Intervention : The patient randomize ( 1:1 ) two group . One group patient receive 15-20mg/kg/day UDCA 24 week . The group receive standard care . Main study endpoint : Proportional change total liver volume UDCA treat patient versus non treated patient , assess CT baseline 6 month . Main secondary outcome variable : - To demonstrate whether UDCA-therapy change absolute total liver volume - To demonstrate whether UDCA-therapy change gastro-intestinal symptom measure GI-questionnaire - To demonstrate whether UDCA-therapy change quality life measure SF-36 - To demonstrate proportion patient reduction total liver volume 24 week - To demonstrate whether UDCA well tolerate - To demonstrate whether UDCA-therapy change absolute total kidney volume ( TKV ) .</brief_summary>
	<brief_title>Ursodeoxycholic Acid Treatment Polycystic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>18 ≤ age ≤ 80 year Polycystic liver disease underlying diagnosis ( PCLD ADPKD ) , define ≥ 20 liver cyst Total liver volume ≥ 2500 mL Symptomatic define ECOGPS ≥ 1 ( 2 ) , least three ten PCLD symptom : Informed consent , patient willing able comply study drug regimen study requirement . Use oral anticonceptives estrogen supplementation Use UDCA 3 month baseline Females pregnant breastfeeding patient reproductive potential employ effective method birth control . Intervention ( aspiration surgical intervention ) within six month baseline Treatment somatostatin analogue within six month baseline Renal dysfunction ( MDRDGFR &lt; 30 ml/min/1.73m2 ) Patients kidney transplant Hypersensitivity reaction UDCA patient galactoseintolerance , lactase deficiency glucosegalactose malabsorption Acute cholecystitis frequent biliary colic attack Acute stomach duodenal ulcer Inflammation small intestine colon Use drug interact UDCA , colestyramine , aluminium hydroxide cyclosporin Enrolment another clinical trial investigational agent participate study History evidence severe illness condition would make patient , opinion investigator , unsuitable study Mental illness interfere patient ability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>